Adalimumab biosimilar market share reached 23% in November 2024, a 1% increase since August. A majority of biosimilar gains are due to Hyrimoz (adalimumab-adaz) and Hadlima (adalimumab-bwwd).

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...